HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,796 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
HUTCHMED (China) Limited의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Le segment de revenus le plus important est HUTCHMED (China) Limited, avec un chiffre d'affaires de Oncology/Immunology - Marketed Products lors du dernier rapport de résultats. En termes géographiques, China est le marché principal pour HUTCHMED (China) Limited, avec un chiffre d'affaires de 3,530,161,153.
HUTCHMED (China) Limited은 수익성이 있나요?
oui, 최신 재무제표에 따르면 HUTCHMED (China) Limited의 순bénéfice은 $456입니다.